NIH R01 · 2025
Metabolic reprogramming of endothelial precursor cells in subretinal fibrosis
Therapeutic agents that target the vascular endothelial growth factor (VEGF) have achieved remarkable success in patients with the neovascular form of age-related macular degeneration (nAMD). An emerging clinical problem, however, is that many of the nAMD patients develop subretinal fibrosis (SRF) after receiving anti-VEGF therapy. SRF can cause irreversible structural damage to the retina and is a major vision- threatening complication with no effective treatment. The disease mechanisms of SRF in nAMD are largely unknown. Transforming growth factor beta (TGF-beta) is a major driver of fibrosis. The source of TGF-beta in SRF, and its main effector cells, have not been well defined. SRF can…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.